Dr Mieke Van Hemelrijck

Mieke Van Hemelrijck is Senior Lecturer in Cancer epidemiology and Head of the Cancer Epidemiology Group at King’s College London. She received an MSc in Biomedical Sciences and an MSc in Statistical Analysis from Ghent University, Belgium. She subsequently obtained an MSc in Population and International Health at the Harvard School of Public health. She completed her PhD in Cancer Epidemiology at King’s College London. In 2012, she was appointed as Lecturer in Cancer Epidemiology at King’s College London. 


Dr Van Hemelrijck’s research interests include prostate cancer, bladder cancer, metabolic and inflammatory biomarkers’ association with risk of all cancer types and particularly, the association between lipid metabolism and risk and progression of prostate cancer. 


Dr Van Hemelrijck coordinates King’s Health Partners Prostate Cancer Research Network and leads the Patho-Epidemiology Group together with Professor Massimo Loda. Her study findings, published in over 600 news articles to date, have had a significant impact on the US Food and Drug Administration safety guidelines for commonly used prostate cancer drugs.

Professor Gordon Rustin MD MSc FRCP

Gordon Rustin is professor of cancer therapy at the Institute of Cancer Research as well as honorary professor at UCL. He received his MBBS from The Middlesex Hospital in 1971 and was appointed senior lecturre in medical oncology at the Charing Cross Hospital and consultant at Mount Vernon Hospital in 1984. He was director of medical oncology at Mount Vernon Hospital from 1995-2015.


Professor Rustin’s special interests are gynaecological cancers and germ cell tumours. He has published over 320 papers on the management of gynaecological and germ cell cancers, use of tumour markers, CA 125 in particular. The use of CA 125 to monitor progression of ovarian carcinoma is used internationally as the “Rustin Criteria”.


He has been Principal Investigator in several clinical trials involving vascular disruptive agents in particular. He was chairman of the NCRI ovarian cancer subgroup for 5 years.

Professor Ian Fentiman MD DSc FRCS

Ian Fentiman is Professor of Surgical Oncology at GKT School of Medicine. He received his MBBS qualification from King’s College Hospital and subsequently trained in general surgery. After receiving his FRCS, he was appointed Clinical Research Fellow at the Imperial Cancer Research Fund. He went on to be appointed Consultant Surgeon at the Guy’s Hospital Breast Unit and eventually became Head of Service and Clinical Lead.


He has pioneered work on breast conserving surgery, cancer treatment in the elderly, the management of ductal carcinoma in situ and the treatment of male breast cancer. As well as being involved in identifying new risk factors for breast cancer and a potential diagnostic blood test for women with breast cancer.


He has been the Principal Investigator of many international clinical trials, published over 300 peer-reviewed papers and written several books. He is a member of the editorial board of the European Journal of Cancer. In 2000, as one of the 100 investigators published most in the 20th century, he was honoured by Cancer Care for advancing treatment of early breast cancer. In 2002 he was awarded Doctorate of Science from the University of London and in 2006 was selected as the best breast surgeon by the London Evening Standard.

Professor Gordon McVie, MD

Professor McVie is widely regarded as a leading international authority in the research and treatment of cancer. Having qualified in the 1960s in science and medicine at Edinburgh University, he was appointed Foundation Senior Lecturer at the Cancer Research Campaign oncology unit at the University of Glasgow in 1975. He trained in the U.S., and spent sabbaticals in Paris, Sydney and Amsterdam.


He is currently Senior Consultant to the European Institute of Oncology, Milan, and is founding editor of ecancer.org, the first free Open Access cancer journal accepted by PubMed. He is visiting professor at the Universities of Milan, Glasgow and Wales.

Previously, Professor McVie was Chief Executive of the Cancer Research Campaign (CRC), which, under his aegis, took over 60 molecules from the lab into clinical trial. He led CRC into a merger with Imperial Cancer Research Fund, which formed Cancer Research UK in 2002, and was joint CEO with Sir Paul Nurse.


In the UK he was one of the architects of the Cancer Trials Networks in Scotland, Wales and England, and was a founding member of the National Cancer Research Institute. Professor McVie is the recipient of numerous awards and has honorary doctorates in science from six universities. He has served on key committees of AACR and ASCO, and on the boards of the National Cancer Institutes of France, Italy and Holland. He has authored 340 peer-reviewed articles, and contributed to over 35 books.


His commitment to drug discovery and delivery is evidenced by approximately 240 patents, including temozolomide, granted to CRC scientists under his leadership, and the foundation of 10 biotechnology companies based on some of that intellectual property. His clinical interests, apart from new drug discovery and chemoprevention, are in the management of cancers of the lung, ovary, colon, breast and brain. He chairs a biotech company in Adelaide, which is taking a saponin derived from a Chinese grass into the clinic, and is a partner with ecancer in 3 FP7 projects on personalized medicine and patient empowerment from the European Commission.

Professor Karl Peggs

Karl Peggs is Professor of Transplant Science and Cancer Immunotherapy at University College London (UCL), Senior Lecturer in Stem Cell Transplantation and Honorary Consultant in Haematology/ Transplantation at UCL Hospitals. He received an MA at Cambridge before completing his MBBS at Oxford University Medical School. He went on to complete his general medical training at Addenbrookes Hospital Cambridge and his specialist haematology training at the John Radcliffe Hospital, Oxford and UCLH.


Professor Pegg’s research interests include adoptive cellular therapies and regulatory checkpoint-directed immotherapy. He runs a research laboratory at UCL Cancer Institute together with Dr Sergio Quezada and established the clinical translational CAR T Cell program at UCLH.


Professor Peggs is Scientific Director at the National Institute of Health Research Body and Transplant Unit for Stem Cells and Immunotherapies, Co-Chair and Board Member of the British Society of Blood and Marrow Transplantation, member of the Anthony Nolan Medical Advisory Board, the NHS Blood and Transplant Stem Cell and Therapeutic Apheresis Strategy Group and is Principal Investigator for several UK Clinical Research Network national studies. 

Please reload

© 2016 by BONUS